Nothing Special   »   [go: up one dir, main page]

TR200103171T2 - Anjiyotensin-(1-7)-reseptörlerinin agonistleri olarak 1-(p-tiyenilbenzil)-imidazoller, imalat yöntemi, kullanımları. - Google Patents

Anjiyotensin-(1-7)-reseptörlerinin agonistleri olarak 1-(p-tiyenilbenzil)-imidazoller, imalat yöntemi, kullanımları.

Info

Publication number
TR200103171T2
TR200103171T2 TR2001/03171T TR200103171T TR200103171T2 TR 200103171 T2 TR200103171 T2 TR 200103171T2 TR 2001/03171 T TR2001/03171 T TR 2001/03171T TR 200103171 T TR200103171 T TR 200103171T TR 200103171 T2 TR200103171 T2 TR 200103171T2
Authority
TR
Turkey
Prior art keywords
arthritis
receptors
thienylbenzyl
angiotensin
imidazoles
Prior art date
Application number
TR2001/03171T
Other languages
English (en)
Inventor
Heitsch Holger
Wiemer Gabriele
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999120815 external-priority patent/DE19920815A1/de
Priority claimed from DE1999161686 external-priority patent/DE19961686A1/de
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of TR200103171T2 publication Critical patent/TR200103171T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bulus formül (I)'in yeni I- (p-tiyenilbenzil) - imidazol'leri ile ilgiliyken, R(1) ila R (6)'ya kadar, X ve Y artiklari tanimlamada verilmis anlamlara sahiptir, anjiyotensin-(1-7)-reseptörlerinin güçlü agonistleridir ve bu reseptörlerinin uyarilmasi yoluyla endotel hücrelerine bagli, damar basincini düsüren, antitrombotik ve kardiyoprotektif tasiyici maddeler, halkali 3', 5' -guvanosinmonofosfat'in (cGMP) ve azotmonoksit'in (NO) üretimi ve açiga birakilmasi yoluyla; yüksek kan basinci, kalp büyümesi, kalp yetmezligi, Anjina Pektoris, kalp krizi, anjiyoplastiden, sonraki vasküler restenoz koroner gibi kalp rahatsizliklarinda kardiyomiyopatilerde, endotelyumla ilgili disfonksiyon ya da endotelyumla ilgili zararlarin, örnegin ateriyosklerotik durumlarin sonucunda ya da diabetis melitus'ta ve ayrica arteriyel ve venöz trombozlarin tedavisi ve/veya profilaksisine yönelik degerli ilaç maddeleri sunmaktadirlar.
TR2001/03171T 1999-05-05 2000-04-29 Anjiyotensin-(1-7)-reseptörlerinin agonistleri olarak 1-(p-tiyenilbenzil)-imidazoller, imalat yöntemi, kullanımları. TR200103171T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999120815 DE19920815A1 (de) 1999-05-05 1999-05-05 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE1999161686 DE19961686A1 (de) 1999-12-21 1999-12-21 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-1(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
TR200103171T2 true TR200103171T2 (tr) 2002-06-21

Family

ID=26053245

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03171T TR200103171T2 (tr) 1999-05-05 2000-04-29 Anjiyotensin-(1-7)-reseptörlerinin agonistleri olarak 1-(p-tiyenilbenzil)-imidazoller, imalat yöntemi, kullanımları.

Country Status (25)

Country Link
US (3) US6235766B1 (tr)
EP (1) EP1185527B1 (tr)
JP (1) JP2002544130A (tr)
KR (1) KR20020012207A (tr)
CN (1) CN1158279C (tr)
AR (1) AR023837A1 (tr)
AT (1) ATE300535T1 (tr)
AU (1) AU775244B2 (tr)
BR (1) BR0010248A (tr)
CA (1) CA2373010A1 (tr)
CZ (1) CZ20013907A3 (tr)
DE (1) DE50010835D1 (tr)
EE (1) EE200100572A (tr)
HK (1) HK1045519B (tr)
HR (1) HRP20010814A2 (tr)
HU (1) HUP0201311A3 (tr)
IL (1) IL146198A0 (tr)
NO (1) NO20015309L (tr)
NZ (1) NZ515242A (tr)
PL (1) PL351609A1 (tr)
RU (1) RU2247121C2 (tr)
SK (1) SK15942001A3 (tr)
TR (1) TR200103171T2 (tr)
WO (1) WO2000068226A1 (tr)
YU (1) YU78601A (tr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630498B2 (en) * 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
DE10112041A1 (de) 2001-03-14 2002-09-26 Aventis Pharma Gmbh p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
JP4707321B2 (ja) * 2001-05-31 2011-06-22 ヴィコール・ファルマ・アーベー アンギオテンシンｉｉアゴニストとして有用な三環式化合物
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
CA2464561A1 (en) * 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
CA2475953A1 (en) * 2002-02-27 2003-09-04 E. Ann Tallant Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
EP1348440A1 (en) * 2002-03-28 2003-10-01 Citeq B.V. Use of angiotensin 1-7 for enhancing cardiac function
NL1021048C2 (nl) 2002-07-11 2004-01-13 Weir Netherlands B V Zuigermembraanpomp.
WO2004046141A1 (en) * 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
AU2003302027A1 (en) * 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
WO2004085420A1 (en) * 2003-03-24 2004-10-07 Vicore Pharma Ab Bicyclic compounds useful as angiotensin ii agonists
DE602005017807D1 (de) 2004-10-21 2009-12-31 Medtronic Inc Angiotensin-(1-7) freisetzende polymerbeschichtete medizinische vorrichtung zur reduzierung von restenose und zur verbesserung von endothelzellfunktionen
KR101429484B1 (ko) * 2005-04-12 2014-08-13 바이코어 파마 아베 신규한 트리시클릭 안지오텐신 ⅱ 아고니스트
BRPI0502497A (pt) * 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
BRPI0602366B1 (pt) * 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
US20100055147A1 (en) * 2006-10-27 2010-03-04 Edze Jan Tijsma Angiotensin (1-7) eluting stent
KR100885197B1 (ko) * 2008-09-25 2009-02-24 박창수 다면다각형상 구현이 용이한 엘이디조명 램프용 인쇄회로기판
ES2393455T3 (es) 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas
CA2859573A1 (en) * 2011-12-16 2013-06-20 Tarix Pharmaceuticals Ltd. Angiotensins for treatment of fibrosis
BR112014019776A2 (pt) * 2012-02-10 2017-06-27 Tarix Pharmaceuticals Ltd composições e métodos para o tratamento de doença vascular periférica
US8557958B1 (en) * 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
WO2014189634A1 (en) * 2013-04-19 2014-11-27 University Of Iowa Research Foundation Angiotensins in muscular dystrophy
CN105451756A (zh) 2013-05-24 2016-03-30 塔瑞克斯制药有限公司 在治疗马凡氏综合征及其相关病症中的血管紧张素肽
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
RU2016152088A (ru) 2014-07-17 2018-08-21 Юниверсити Оф Саузерн Калифорния Способы, соединения и композиции для лечения заболеваний опорно-двигательного аппарата
WO2017066552A1 (en) 2015-10-14 2017-04-20 Tarix Pharmaceuticals Ltd. Methods and compositions for the treatment of epidermolysis bullosa
EA039493B1 (ru) 2016-06-29 2022-02-02 Университе Де Монреаль Биарилметильные гетероциклы
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
GB201913603D0 (en) * 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
WO2021183863A1 (en) 2020-03-13 2021-09-16 Constant Therapeutics Llc Methods and compositions for treatment of coronavirus infection
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5252574A (en) 1991-04-26 1993-10-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
WO1994027597A1 (en) * 1993-05-21 1994-12-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acid angiotensin ii receptor antagonists
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.

Also Published As

Publication number Publication date
YU78601A (sh) 2005-07-19
PL351609A1 (en) 2003-05-05
US6235766B1 (en) 2001-05-22
US6429222B2 (en) 2002-08-06
CA2373010A1 (en) 2000-11-16
AU775244B2 (en) 2004-07-22
US20020077344A1 (en) 2002-06-20
ATE300535T1 (de) 2005-08-15
HK1045519B (zh) 2005-04-22
KR20020012207A (ko) 2002-02-15
HUP0201311A2 (en) 2002-10-28
HK1045519A1 (en) 2002-11-29
SK15942001A3 (sk) 2002-04-04
AR023837A1 (es) 2002-09-04
NZ515242A (en) 2003-11-28
JP2002544130A (ja) 2002-12-24
EP1185527B1 (de) 2005-07-27
DE50010835D1 (de) 2005-09-01
IL146198A0 (en) 2002-07-25
CN1158279C (zh) 2004-07-21
EE200100572A (et) 2003-02-17
AU4753600A (en) 2000-11-21
HUP0201311A3 (en) 2003-03-28
WO2000068226A1 (de) 2000-11-16
CZ20013907A3 (cs) 2002-02-13
CN1349530A (zh) 2002-05-15
EP1185527A1 (de) 2002-03-13
NO20015309L (no) 2001-12-28
BR0010248A (pt) 2002-02-13
HRP20010814A2 (en) 2003-02-28
US20010018449A1 (en) 2001-08-30
RU2247121C2 (ru) 2005-02-27
NO20015309D0 (no) 2001-10-30

Similar Documents

Publication Publication Date Title
TR200103171T2 (tr) Anjiyotensin-(1-7)-reseptörlerinin agonistleri olarak 1-(p-tiyenilbenzil)-imidazoller, imalat yöntemi, kullanımları.
TR200100147T2 (tr) Sülfür ile ikame edilmiş sülfonilaminokarboksilik asit N-arilamidleri
ATE193443T1 (de) Verwendung eines imidazols zur herstellung eines medikamentes zur behandlung der arteriosklerose
IL143086A0 (en) Bioactive impants, particularly with immunosuppresive, antistenotic and antithrombotic properties, and the production of said implants
FR2766716B1 (fr) Prothese composite pour la prevention des adherences post-chirurgicales et son procede d'obtention
FR2766717B1 (fr) Prothese composite pour la prevention des adherences post-chirurgicales et son procede d'obtention
TW372232B (en) Phenylalanine derivatives
ATE66350T1 (de) Suessware und verfahren zur herstellung derselben.
PL376224A1 (en) Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase
ATE346686T1 (de) Lösliche hydrokolloidale nahrungsmittelzusätze und ihre herstellung
AU2002365503A1 (en) Adhesive polymer composition
AU4021393A (en) Metal coatings
GR3024757T3 (en) Novel heparin derivatives and process for the preparation thereof
ATE224918T1 (de) Zusammensetzung zur hemmung der thromboseentstehung
DE69911656D1 (de) Verfahren zur herstellung eines hydraulischen bindemittels auf der basis von anhydrite iii oder alpha und damit hergestelltes bindemittel
DE69803805D1 (de) Neues material und verfahren zu dessen herstellung
DK1061803T3 (da) Eprosartansammensætninger
ITMI20021801A1 (it) Prodotti di pomodoro.
ATE352090T1 (de) Verfahren zum herstellen eines kontaktwerkstoffes für kontaktstücke für vakuumschaltgeräte sowie kontaktwerkstoff und kontaktstücke hierfür
FR2400059A1 (fr) Compositions de revetements et de liaison
ATE27007T1 (de) Verfahren zum abscheiden von niederkaraetigen, glaenzenden gold-silber-legierungsueberzuegen.
YU3701A (sh) Supstituisani fenilamidini sa antitrombskim dejstvom
ATE33496T1 (de) Verfahren zur herstellung von organischen oligosacchariden uebereinstimmend mit fragmenten von natuerlichen muco-polysacchariden, die erhaltenen oligosaccharide und ihre biologische verwendung.
DK176390D0 (da) Pyrazindiazohydroxidforbindelser
IE832294L (en) Electroplated steel exhibiting low hydrogen embrittlement.